1-8 of 8
Renier Brentjens, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Influence of National Comprehensive Cancer Network (NCCN) Guidelines on Clinical Practice in Patients with Chronic Myelogenous Leukemia (CML) Treated At a Single Academic Medical Center

Ellin Berman, MD, Cyrus V. Hedvat, MD, PhD, Joseph G. Jurcic, MD, Mark Heaney, MD, PhD, Peter G. Maslak, M.D., Renier Brentjens, MD, PhD, Nicole Lamanna, MD, Todd L. Rosenblat, MD, Mark G. Frattini, MD, PhD, Ann A Jakubowski, MD, PhD, Suresh Jhanwar, PhD
Journal: Blood
Blood (2011) 118 (21): 4433.
https://doi.org/10.1182/blood.V118.21.4433.4433
Published: 2011
Journal Articles

In Vivo comparison of 3 Suicide Gene-Prodrug Combinations in a Mouse Graft-Versus-Host-Disease Model

Jae H. Park, MD, Raymond Yeh, PhD, Isabelle Riviere, PhD, Michel Sadelain, MD, PhD, Renier Brentjens, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 3121.
https://doi.org/10.1182/blood.V118.21.3121.3121
Published: 2011
Journal Articles

Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History

Jeffrey R Gardner, MBA, Kristina Knapp, Mark G. Frattini, MD, PhD, Nicole Lamanna, MD, Renier Brentjens, MD, PhD, Joseph G Jurcic, MD, Peter G. Maslak, M.D., Ellin Berman, MD, Mark Weiss, MD, David A. Scheinberg, MD, PhD, Mark Heaney, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 1765.
https://doi.org/10.1182/blood.V118.21.1765.1765
Published: 2011
Journal Articles

Adoptive Therapy with Human CD19 (hCD19)-Targeted T Cells Further Modified to Express IL-12 Overcome the Need for Prior Lymphodepletion to Eradicate Established hCD19 + Tumors and Induce B Cell Aplasias In Immune Competent hCD19 + Transgenic Mice

Erik Hayman, BS, James Lee, MD, Hollie J. Pegram, PhD, Renier Brentjens, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 2097.
https://doi.org/10.1182/blood.V116.21.2097.2097
Published: 2010
Journal Articles

Characteristic Proinflammatory Serum Cytokine Profiles In Patients with B-Cell Chronic Lymphocytic Leukemia

James J. Harding, MD, Raymond Yeh, PhD, Yan Nikhamin, MS, MBA, Mark Frattini, MD, Nicole Lamanna, MD, Joseph G Jurcic, MD, Mark Heaney, MD, PhD, Renier Brentjens, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3595.
https://doi.org/10.1182/blood.V116.21.3595.3595
Published: 2010
Journal Articles

CD19 Targeted Cord Blood Derived T Cells for Cancer Immunotherapy.

Hollie J. Pegram, PhD, Vincent LaRussa, PhD, Renier Brentjens, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3767.
https://doi.org/10.1182/blood.V116.21.3767.3767
Published: 2010
Journal Articles

Efficacy and Long Term Survival of Genetically Modified T Cells Targeting CD19 in a Syngeneic Immune Competent Transgenic Murine Tumor Model Is Dependent on Prior Lymphodepleting Chemotherapy.

James Lee, BA, Yan Nikhamin, MS, Gavin Imperato, MS, Adam Cohen, MD, Michel Sadelain, MD/PhD, Renier Brentjens, MD/PhD
Journal: Blood
Blood (2007) 110 (11): 2754.
https://doi.org/10.1182/blood.V110.11.2754.2754
Published: 2007
Journal Articles

Pentostatin, Cyclophosphamide, and Rituximab (PCR) Has Comparable Activity but Appears To Be Better Tolerated Than Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Previously Treated Chronic Lymphocytic Leukemia.

Nicole Lamanna, MD, Matt Kalaycio, MD, Peter Maslak, MD, Mark L. Heaney, MD, PhD, Renier Brentjens, MD, PhD, Joseph Jurcic, MD, Emily Biederman, Alison N. Gencarelli, RN, Katherine S. Panageas, PhD, David A. Scheinberg, MD, PhD, Mark A. Weiss, MD
Journal: Blood
Blood (2005) 106 (11): 2127.
https://doi.org/10.1182/blood.V106.11.2127.2127
Published: 2005